Business Context and Reporting Period
This Form 8-K Current Report was filed by Lantheus Holdings, Inc. on March 4, 2021, covering events occurring on February 28, 2021. The filing addresses corporate governance changes related to the company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel change and does not contain financial performance data.
Material Changes
The primary material change reported is the resignation of Dr. Fredrick Robertson from the Board of Directors. This action is being taken to fulfill a requirement under the Amended and Restated Agreement and Plan of Merger dated February 20, 2020, between Lantheus, Plato Merger Sub, Inc., and Progenics Pharmaceuticals, Inc. The Merger Agreement mandates reducing the Board size from nine to eight directors prior to the 2021 Annual Meeting of Stockholders, scheduled for April 28, 2021.
Management Commentary and Risks
Management explicitly states that Dr. Robertson's resignation is not the result of any disagreement with Lantheus regarding its operations, policies, or practices. The resignation is effective immediately prior to the Annual Meeting. No other risks, contingencies, or unusual items are disclosed in this specific filing.
Investor Verification Checklist
- Verify the scheduled date of the 2021 Annual Meeting of Stockholders (April 28, 2021).
- Confirm the updated composition of the Board of Directors following the reduction from nine to eight members.
- Review the terms of the Merger Agreement with Progenics Pharmaceuticals, Inc. to understand the context of the Board size reduction.
- Check subsequent filings for the election of any new directors to fill the vacancy, if applicable.